ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Progenics Pharmaceuticals, Inc." (PGNX) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Progenics Pharmaceuticals, Inc." (PGNX)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: UTHR, MNOV, CMRX, RNA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Progenics Pharmaceuticals, Inc."© quotemedia

Company Profile

Progenics Pharmaceuticals, Inc. engages in research and development of biotechnology product candidates in the areas of oncology, virology, supportive care, and gastroenterology worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer. It is also developing RELISTOR, a subcutaneous injection for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. The company’s principal product candidate under development is PSMA ADC, which is in Phase I trial in men with advanced prostate cancer. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer tumor cells, as well as on the neovasculature of various other types of solid tumors. In addition, the company is developing PI3K, a pre-clinical stage novel multiplex phosphoinositide 3-kinase inhibitor for blocking signaling pathways that are critical in the growth of aggressive cancers. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

Recent News: "Progenics Pharmaceuticals, Inc."